These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 12855656

  • 1. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
    London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM.
    Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
    [Abstract] [Full Text] [Related]

  • 2. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN, Michels GM.
    Clin Cancer Res; 2009 Jun 01; 15(11):3856-65. PubMed ID: 19470739
    [Abstract] [Full Text] [Related]

  • 3. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
    Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington JM, London CA.
    Clin Cancer Res; 2003 Nov 15; 9(15):5729-34. PubMed ID: 14654558
    [Abstract] [Full Text] [Related]

  • 4. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
    Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD.
    Clin Cancer Res; 2004 Sep 01; 10(17):5732-40. PubMed ID: 15355900
    [Abstract] [Full Text] [Related]

  • 6. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
    Hoekstra R, Dumez H, Eskens FA, van der Gaast A, Planting AS, de Heus G, Sizer KC, Ravera C, Vaidyanathan S, Bucana C, Fidler IJ, van Oosterom AT, Verweij J.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):6908-15. PubMed ID: 16203782
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
    Yancey MF, Merritt DA, Lesman SP, Boucher JF, Michels GM.
    J Vet Pharmacol Ther; 2010 Apr 01; 33(2):162-71. PubMed ID: 20444041
    [Abstract] [Full Text] [Related]

  • 8. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H.
    J Clin Oncol; 2009 Sep 01; 27(25):4169-76. PubMed ID: 19636022
    [Abstract] [Full Text] [Related]

  • 9. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.
    Krystal GW, Honsawek S, Kiewlich D, Liang C, Vasile S, Sun L, McMahon G, Lipson KE.
    Cancer Res; 2001 May 01; 61(9):3660-8. PubMed ID: 11325836
    [Abstract] [Full Text] [Related]

  • 10. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 11. Catching cancer by the tail: new perspectives on the use of kinase inhibitors.
    Khanna C, Gordon I.
    Clin Cancer Res; 2009 Jun 01; 15(11):3645-7. PubMed ID: 19470723
    [Abstract] [Full Text] [Related]

  • 12. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
    Leblanc AK, Miller AN, Galyon GD, Moyers TD, Long MJ, Stuckey AC, Wall JS, Morandi F.
    Vet Radiol Ultrasound; 2012 Jun 01; 53(3):348-57. PubMed ID: 22360684
    [Abstract] [Full Text] [Related]

  • 13. Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies.
    Kuenen BC, Giaccone G, Ruijter R, Kok A, Schalkwijk C, Hoekman K, Pinedo HM.
    Clin Cancer Res; 2005 Sep 01; 11(17):6240-6. PubMed ID: 16144927
    [Abstract] [Full Text] [Related]

  • 14. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A, Zeng Y, Ihnat M, Warnke LA, Green DW, Kisliuk RL, Lin FT.
    Bioorg Med Chem; 2005 Sep 15; 13(18):5475-91. PubMed ID: 16039863
    [Abstract] [Full Text] [Related]

  • 15. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models.
    Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, Nordahl L, Garrett E, Samara E, Aukerman SL, Gelb AB, Heise C.
    Clin Cancer Res; 2005 May 15; 11(10):3633-41. PubMed ID: 15897558
    [Abstract] [Full Text] [Related]

  • 16. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
    Coxon A, Bush T, Saffran D, Kaufman S, Belmontes B, Rex K, Hughes P, Caenepeel S, Rottman JB, Tasker A, Patel V, Kendall R, Radinsky R, Polverino A.
    Clin Cancer Res; 2009 Jan 01; 15(1):110-8. PubMed ID: 19118038
    [Abstract] [Full Text] [Related]

  • 17. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
    O'Farrell AM, Yuen HA, Smolich B, Hannah AL, Louie SG, Hong W, Stopeck AT, Silverman LR, Lancet JE, Karp JE, Albitar M, Cherrington JM, Giles FJ.
    Leuk Res; 2004 Jul 01; 28(7):679-89. PubMed ID: 15158089
    [Abstract] [Full Text] [Related]

  • 18. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.
    Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LK, Cherrington JM.
    Anticancer Drug Des; 2000 Feb 01; 15(1):29-41. PubMed ID: 10888034
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
    Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS.
    J Clin Oncol; 2007 Jun 10; 25(17):2369-76. PubMed ID: 17557949
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.